Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Addition of trastuzumab to adjuvant chemotherapy has dramatically reduced the risk of recurrence and has become the standard of care for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer patients. Since most data on trastuzumab benefits come from clinical trials, conducted...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vici, Patrizia, Pizzuti, Laura, Natoli, Clara, Moscetti, Luca, Mentuccia, Lucia, Vaccaro, Angela, Sergi, Domenico, Di Lauro, Luigi, Trenta, Patrizia, Seminara, Patrizia, Santini, Daniele, Iezzi, Laura, Tinari, Nicola, Bertolini, Ilaria, Sini, Valentina, Mottolese, Marcella, Giannarelli, Diana, Giotta, Francesco, Maugeri-Saccà, Marcello, Barba, Maddalena, Marchetti, Paolo, Michelotti, Andrea, Sperduti, Isabella, Gamucci, Teresa
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2014
Matèries:
Clinical Trial
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4174332/
https://ncbi.nlm.nih.gov/pubmed/25234842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3133-1
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars